Interdisciplinary approach to surgical treatment for patients with hypertrophic obstructive cardiomyopathy

Authors

DOI:

https://doi.org/10.14739/2310-1210.2021.4.232632

Keywords:

hypertrophic cardiomyopathy, septal myectomy, mitral regurgitation, sudden cardiac death

Abstract

Hypertrophic cardiomyopathy (HCM) – is the most common genetically determined heart disease, characterized by symmetrical or asymmetrical myocardial thickening (≥15 mm), leading to progressive heart failure and a high risk of sudden cardiac death (SCD).

Diagnosis, natural course and treatment of HCM have become sources of uncertainty, misunderstanding and debate due to the increasing complexity of diagnosis in clinical practice, international differences in strategic approaches, advances in the treatment of genetic diseases and cardiac imaging.

The aim. To amplify the current concept of HCM pathogenesis and mechanisms of the left ventricular outflow tract (LVOT) obstruction as well as to highlight our own results of HCM surgical correction.

Materials and methods. A total of 330 HCM patients underwent surgical correction (septal myectomy) in the National M. Amosov Institute of Cardiovascular Surgery affiliated to National Academy of Medical Sciences of Ukraine. The mean age of the patients was 49.7 ± 15.0 years, median – 53; 168 (50.9 %) were male.

Results. Surgical correction of HCM significantly improves the quality of life (80 % of patients were in NYHA II functional class after correction), reduces the symptoms of heart failure (93 % of patients had minimal mitral regurgitation after septal myectomy), decreases LVOT systolic pressure gradient (SPG) (the mean SPG was 18.9 ± 8.5 mmHg versus preoperative 93.6 ± 23.2 mmHg) and lowers the high-risk for SCD in the patients (the mean percentage of high-risk group was 3.78 % after
correction).

Routine CT planning and intraoperative transesophageal echocardiography helps to avoid severe iatrogenic complications and resect the interventricular septum as accurately as possible, completely eliminating LVOT obstruction.

Conclusions. Secondary abnormal chordal attachment cutting, papillary muscle realignment and anterior mitral leaflet plication along with septal myectomy allows to fully correct all phenotype of HCM, is the safe and effective procedure as well as the definitive method of this pathology treatment minimizing the risk of disease recurrence.

Author Biographies

K. V. Rudenko, National M. Amosov Institute of Cardiovascular Surgery affiliated to National Academy of Medical Sciences of Ukraine, Kyiv

MD, PhD, DSc, Professor, Deputy Director of Therapeutic and Coordinating Work

L. O. Nevmerzhytska, National M. Amosov Institute of Cardiovascular Surgery affiliated to National Academy of Medical Sciences of Ukraine, Kyiv

MD, PhD, Junior Researcher

M. V. Kozhanov, National M. Amosov Institute of Cardiovascular Surgery affiliated to National Academy of Medical Sciences of Ukraine, Kyiv

MD, Anesthesiologist

M. О. Tregubova, National M. Amosov Institute of Cardiovascular Surgery affiliated to National Academy of Medical Sciences of Ukraine, Kyiv

MD, Radiologist

P. А. Danchenko, Bogomolets National Medical University, Kyiv, Ukraine

Senior Laboratory Assistant

References

  1. Veselka, J., Anavekar, N. S., & Charron, P. (2017). Hypertrophic obstructive cardiomyopathy. The Lancet, 389(10075), 1253-1267. https://doi.org/10.1016/S0140-6736(16)31321-6
  2. Maron, B. J., & Maron, M. S. (2013). Hypertrophic cardiomyopathy. The Lancet, 381(9862), 242-255. https://doi.org/10.1016/S0140-6736(12)60397-3
  3. Alcalai, R., Seidman, J. G., & Seidman, C. E. (2008). Genetic Basis of Hypertrophic Cardiomyopathy: From Bench to the Clinics. Journal of Cardiovascular Electrophysiology, 19(1), 104-110. https://doi.org/10.1111/j.1540-8167.2007.00965.x
  4. Seidman, C. E., & Seidman, J. G. (2011). Identifying Sarcomere Gene Mutations in Hypertrophic Cardiomyopathy: A Personal History. Circulation Research, 108(6), 743-750. https://doi.org/10.1161/CIRCRESAHA.110.223834
  5. Ackerman, M. J., VanDriest, S. L., Ommen, S. R., Will, M. L., Nishimura, R. A., Tajik, A. J., & Gersh, B. J. (2002). Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. Journal of the American College of Cardiology, 39(12), 2042-2048. https://doi.org/10.1016/s0735-1097(02)01900-9
  6. Niimura, H., Bachinski, L. L., Sangwatanaroj, S., Watkins, H., Chudley, A. E., McKenna, W., Kristinsson, A., Roberts, R., Sole, M., Maron, B. J., Seidman, J. G., & Seidman, C. E. (1998). Mutations in the Gene for Cardiac Myosin-Binding Protein C and Late-Onset Familial Hypertrophic Cardiomyopathy. The New England Journal of Medicine, 338(18), 1248-1257. https://doi.org/10.1056/NEJM199804303381802
  7. Van Driest, S. L., Ackerman, M. J., Ommen, S. R., Shakur, R., Will, M. L., Nishimura, R. A., Tajik, A. J., & Gersh, B. J. (2002). Prevalence and Severity of “Benign” Mutations in the β-Myosin Heavy Chain, Cardiac Troponin T, and α-Tropomyosin Genes in Hypertrophic Cardiomyopathy. Circulation, 106(24), 3085-3090. https://doi.org/10.1161/01.cir.0000042675.59901.14
  8. Landstrom, A. P., & Ackerman, M. J. (2010). Mutation Type Is Not Clinically Useful in Predicting Prognosis in Hypertrophic Cardiomyopathy. Circulation, 122(23), 2441-2450. https://doi.org/10.1161/CIRCULATIONAHA.110.954446
  9. Richard, P., Charron, P., Carrier, L., Ledeuil, C., Cheav, T., Pichereau, C., Benaiche, A., Isnard, R., Dubourg, O., Burban, M., Gueffet, J. P., Millaire, A., Desnos, M., Schwartz, K., Hainque, B., Komajda, M., & EUROGENE Heart Failure Project. (2003). Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy. Circulation, 107(17), 2227-2232. https://doi.org/10.1161/01.CIR.0000066323.15244.54
  10. Maron, M. S., Maron, B. J., Harrigan, C., Buros, J., Gibson, C. M., Olivotto, I., Biller, L., Lesser, J. R., Udelson, J. E., Manning, W. J., & Appelbaum, E. (2009). Hypertrophic Cardiomyopathy Phenotype Revisited After 50 Years With Cardiovascular Magnetic Resonance. Journal of the American College of Cardiology, 54(3), 220-228. https://doi.org/10.1016/j.jacc.2009.05.006
  11. Rickers, C., Wilke, N. M., Jerosch-Herold, M., Casey, S. A., Panse, P., Panse, N., Weil, J., Zenovich, A. G., & Maron, B. J. (2005). Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Hypertrophic Cardiomyopathy. Circulation, 112(6), 855-861. https://doi.org/10.1161/CIRCULATIONAHA.104.507723
  12. Moon, J. C., Fisher, N. G., McKenna, W. J., & Pennell, D. J. (2004). Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart, 90(6), 645-649. https://doi.org/10.1136/hrt.2003.014969
  13. Valeti, U. S., Nishimura, R. A., Holmes, D. R., Araoz, P. A., Glockner, J. F., Breen, J. F., Ommen, S. R., Gersh, B. J., Tajik, A. J., Rihal, C. S., Schaff, H. V., & Maron, B. J. (2007). Comparison of Surgical Septal Myectomy and Alcohol Septal Ablation With Cardiac Magnetic Resonance Imaging in Patients With Hypertrophic Obstructive Cardiomyopathy. Journal of the American College of Cardiology, 49(3), 350-357. https://doi.org/10.1016/j.jacc.2006.08.055
  14. Maron, B. J., Seidman, C. E., Ackerman, M. J., Towbin, J. A., Maron, M. S., Ommen, S. R., Nishimura, R. A., & Gersh, B. J. (2009). How should hypertrophic cardiomyopathy be classified? What’s in a Name? Dilemmas in Nomenclature Characterizing Hypertrophic Cardiomyopathy and Left Ventricular Hypertrophy. Circulation. Cardiovascular Genetics, 2(1), 81-86. https://doi.org/10.1161/CIRCGENETICS.108.788703
  15. Ommen, S. R., Mital, S., Burke, M. A., Day, S. M., Deswal, A., Elliott, P., Evanovich, L. L., Hung, J., Joglar, J. A., Kantor, P., Kimmelstiel, C., Kittleson, M., Link, M. S., Maron, M. S., Martinez, M. W., Miyake, C. Y., Schaff, H. V., Semsarian, C., & Sorajja, P. (2020). 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 142(25), e558-e631. https://doi.org/10.1161/CIR.0000000000000937
  16. Maron, B. J., Nishimura, R. A., McKenna, W. J., Rakowski, H., Josephson, M. E., & Kieval, R. S. (1999). Assessment of Permanent Dual-Chamber Pacing as a Treatment for Drug-Refractory Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. A Randomized, Double-Blind, Crossover Study (M-PATHY). Circulation, 99(22), 2927-2933. https://doi.org/10.1161/01.cir.99.22.2927
  17. Semsarian, C., Ingles, J., Maron, M. S., & Maron, B. J. (2015). New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 65(12), 1249-1254. https://doi.org/10.1016/j.jacc.2015.01.019
  18. Marian, A. J., & Braunwald, E. (2017). Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circulation Research, 121(7), 749-770. https://doi.org/10.1161/CIRCRESAHA.117.311059
  19. Maron, B. J. (2018). Clinical Course and Management of Hypertrophic Cardiomyopathy. The New England Journal of Medicine, 379(7), 655-668. https://doi.org/10.1056/NEJMra1710575
  20. Maron, M. S., Rowin, E. J., Lin, D., Appelbaum, E., Chan, R. H., Gibson, C. M., Lesser, J. R., Lindberg, J., Haas, T. S., Udelson, J. E., Manning, W. J., & Maron, B. J. (2012). Prevalence and Clinical Profile of Myocardial Crypts in Hypertrophic Cardiomyopathy. Circulation. Cardiovascular imaging, 5(4), 441-447. https://doi.org/10.1161/CIRCIMAGING.112.972760
  21. Authors/Task Force members, Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., Mahrholdt, H., McKenna, W. J., Mogensen, J., Nihoyannopoulos, P., Nistri, S., Pieper, P. G., Pieske, B., Rapezzi, C., Rutten, F. H., Tillmanns, C., … Watkins, H. (2014). 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European Heart Journal, 35(39), 2733-2779. https://doi.org/10.1093/eurheartj/ehu284
  22. McCann, G. P., Van Dockum, W. G., Beek, A. M., Nijveldt, R., Ten Cate, F. J., Ten Berg, J. M., & Van Rossum, A. C. (2007). Extent of Myocardial Infarction and Reverse Remodeling Assessed by Cardiac Magnetic Resonance in Patients With and Without Right Bundle Branch Block Following Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy. The American Journal of Cardiology, 99(4), 563-567. https://doi.org/10.1016/j.amjcard.2006.08.067
  23. Sen-Chowdhry, S., Jacoby, D., Moon, J. C., & McKenna, W. J. (2016). Update on hypertrophic cardiomyopathy and a guide to the guidelines. Nature Reviews Cardiology, 13(11), 651-675. https://doi.org/10.1038/nrcardio.2016.140
  24. Biagini, E., Spirito, P., Rocchi, G., Ferlito, M., Rosmini, S., Lai, F., Lorenzini, M., Terzi, F., Bacchi-Reggiani, L., Boriani, G., Branzi, A., Boni, L., & Rapezzi, C. (2009). Prognostic Implications of the Doppler Restrictive Filling Pattern in Hypertrophic Cardiomyopathy. The American Journal of Cardiology, 104(12), 1727-1731. https://doi.org/10.1016/j.amjcard.2009.07.057
  25. Braunwald, E., & Aygen, M. M. (1963). Idiopathic myocardial hypertrophy without congestive heart failure or obstruction to blood flow. Clinical, hemodynamic and angiocardiographic studies in fourteen patients. The American Journal of Medicine, 35(1), 7-19. https://doi.org/10.1016/0002-9343(63)90159-1
  26. Maron, B. J., Rowin, E. J., Maron, M. S., & Braunwald, E. (2017). Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored … Until Now. The American Journal of Medicine, 130(2), 119-123. https://doi.org/10.1016/j.amjmed.2016.09.015
  27. Maron, M. S., Rowin, E. J., Olivotto, I., Casey, S. A., Arretini, A., Tomberli, B., Garberich, R. F., Link, M. S., Chan, R., Lesser, J. R., & Maron, B. J. (2016). Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 67(12), 1399-1409. https://doi.org/10.1016/j.jacc.2016.01.023
  28. Monserrat, L., Elliott, P. M., Gimeno, J. R., Sharma, S., Penas-Lado, M., & McKenna, W. J. (2003). Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. Journal of the American College of Cardiology, 42(5), 873-879. https://doi.org/10.1016/s0735-1097(03)00827-1
  29. Adabag, A. S., Casey, S. A., Kuskowski, M. A., Zenovich, A. G., & Maron, B. J. (2005). Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 45(5), 697-704. https://doi.org/10.1016/j.jacc.2004.11.043
  30. Elliott, P. M., Poloniecki, J., Dickie, S., Sharma, S., Monserrat, L., Varnava, A., Mahon, N. G., & McKenna, W. J. (2000). Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. Journal of the American College of Cardiology, 36(7), 2212-2218. https://doi.org/10.1016/s0735-1097(00)01003-2
  31. Christiaans, I., van Engelen, K., van Langen, I. M., Birnie, E., Bonsel, G. J., Elliott, P. M., & Wilde, A. A. (2010). Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. EP Europace, 12(3), 313-321. https://doi.org/10.1093/europace/eup431
  32. O'Mahony, C., Jichi, F., Pavlou, M., Monserrat, L., Anastasakis, A., Rapezzi, C., Biagini, E., Gimeno, J. R., Limongelli, G., McKenna, W. J., Omar, R. Z., Elliott, P. M., & Hypertrophic Cardiomyopathy Outcomes Investigators. (2014). A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). European Heart Journal, 35(30), 2010-2020. https://doi.org/10.1093/eurheartj/eht439
  33. Nienaber, C. A., Hiller, S., Spielmann, R. P., Geiger, M., & Kuck, K. H. (1990). Syncope in hypertrophic cardiomyopathy: multivariate analysis of prognostic determinants. Journal of the American College of Cardiology, 15(5), 948-955. https://doi.org/10.1016/0735-1097(90)90222-b
  34. Olivotto, I., Cecchi, F., Casey, S. A., Dolara, A., Traverse, J. H., & Maron, B. J. (2001). Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy. Circulation, 104(21), 2517-2524. https://doi.org/10.1161/hc4601.097997
  35. Debonnaire, P., Joyce, E., Hiemstra, Y., Mertens, B. J., Atsma, D. E., Schalij, M. J., Bax, J. J., Delgado, V., & Marsan, N. A. (2017). Left Atrial Size and Function in Hypertrophic Cardiomyopathy Patients and Risk of New-Onset Atrial Fibrillation. Circulation. Arrhythmia and Electrophysiology, 10(2), Article e004052. https://doi.org/10.1161/CIRCEP.116.004052
  36. Guttmann, O. P., Rahman, M. S., O'Mahony, C., Anastasakis, A., & Elliott, P. M. (2014). Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart, 100(6), 465-472. https://doi.org/10.1136/heartjnl-2013-304276
  37. Eriksson, M. J., Sonnenberg, B., Woo, A., Rakowski, P., Parker, T. G., Wigle, E. D., & Rakowski, H. (2002). Long-term outcome in patients with apical hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 39(4), 638-645. https://doi.org/10.1016/s0735-1097(01)01778-8
  38. Maron, B. J., Wolfson, J. K., Epstein, S. E., & Roberts, W. C. (1986). Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 8(3), 545-557. https://doi.org/10.1016/s0735-1097(86)80181-4
  39. Grazioli, G., Usín, D., Trucco, E., Sanz, M., Montserrat, S., Vidal, B., Gutierrez, J., Canal, R., Brugada, J., Mont, L., & Sitges, M. (2016). Differentiating hypertrophic cardiomyopathy from athlete's heart: An electrocardiographic and echocardiographic approach. Journal of Electrocardiology, 49(4), 539-544. https://doi.org/10.1016/j.jelectrocard.2016.03.005
  40. Maron, B. J., Doerer, J. J., Haas, T. S., Tierney, D. M., & Mueller, F. O. (2009). Sudden Deaths in Young Competitive Athletes: Analysis of 1866 Deaths in the United States, 1980-2006. Circulation, 119(8), 1085-1092. https://doi.org/10.1161/CIRCULATIONAHA.108.804617
  41. Maron, B. J., Shirani, J., Poliac, L. C., Mathenge, R., Roberts, W. C., & Mueller, F. O. (1996). Sudden Death in Young Competitive Athletes. Clinical, Demographic, and Pathological Profiles. JAMA, 276(3), 199-204. https://doi.org/10.1001/jama.1996.03540030033028
  42. Caselli, S., Maron, M. S., Urbano-Moral, J. A., Pandian, N. G., Maron, B. J., & Pelliccia, A. (2014). Differentiating Left Ventricular Hypertrophy in Athletes from That in Patients With Hypertrophic Cardiomyopathy. The American Journal of Cardiology, 114(9), 1383-1389. https://doi.org/10.1016/j.amjcard.2014.07.070
  43. Butz, T., van Buuren, F., Mellwig, K. P., Langer, C., Plehn, G., Meissner, A., Trappe, H. J., Horstkotte, D., & Faber, L. (2011). Two-dimensional strain analysis of the global and regional myocardial function for the differentiation of pathologic and physiologic left ventricular hypertrophy: a study in athletes and in patients with hypertrophic cardiomyopathy. The International Journal of Cardiovascular Imaging, 27(1), 91-100. https://doi.org/10.1007/s10554-010-9665-5
  44. Petersen, S. E., Selvanayagam, J. B., Francis, J. M., Myerson, S. G., Wiesmann, F., Robson, M. D., Ostman-Smith, I., Casadei, B., Watkins, H., & Neubauer, S. (2005). Differentiation of athlete's heart from pathological forms of cardiac hypertrophy by means of geometric indices derived from cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 7(3), 551-558. https://doi.org/10.1081/jcmr-200060631
  45. Sheikh, N., Papadakis, M., Ghani, S., Zaidi, A., Gati, S., Adami, P. E., Carré, F., Schnell, F., Wilson, M., Avila, P., McKenna, W., & Sharma, S. (2014). Comparison of Electrocardiographic Criteria for the Detection of Cardiac Abnormalities in Elite Black and White Athletes. Circulation, 129(16), 1637-1649. https://doi.org/10.1161/CIRCULATIONAHA.113.006179

Downloads

Published

2021-07-01

How to Cite

1.
Rudenko KV, Nevmerzhytska LO, Kozhanov MV, Tregubova MО, Danchenko PА. Interdisciplinary approach to surgical treatment for patients with hypertrophic obstructive cardiomyopathy. Zaporozhye Medical Journal [Internet]. 2021Jul.1 [cited 2026May20];23(4):492-50. Available from: https://zmj.zsmu.edu.ua/article/view/232632

Issue

Vol. 23 No. 4 (2021)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons